<DOC>
	<DOCNO>NCT00833482</DOCNO>
	<brief_summary>This study assess effect voriconazole , 200 mg , administer twice daily ( BID ) , steady-state pharmacokinetics atazanavir administer atazanavir/ritonavir , 300/100 mg daily ( QD ) , healthy participant functional CYP2C19 allele . The study also review effect atazanavir/ritonavir , 300/100 mg QD , pharmacokinetics voriconazole , 200 mg , BID healthy participant functional CYP2C19 allele .</brief_summary>
	<brief_title>Drug Interactions Between Voriconazole Atazanavir Coadministered Atazanavir/Ritonavir Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Healthy participant determine clinically significant deviation normal Body Mass Index ( BMI ) 18 32 kg/m^2 , inclusive . BMI=weight ( kg ) /height ( ) ^2 Women childbearing potential ( WOCBP ) ( ie , postmenopausal surgically sterile ) men , age 18 45 year , inclusive WOCBP Sexually active fertile men use effective birth control partner WOCBP Proven suspect acute hepatitis ( within 12 month prior 1st dose ) Any significant acute chronic medical illness Any gastrointestinal surgery could impact absorption study drug Smoking 5 cigarette per day History hemolytic disorder ( include druginduced hemolysis ) History acute chronic pancreatitis History hypochlorhydria achlorhydria Men woman weigh &lt; 40 kg Positive blood screen hepatitis C antibody , hepatitis B surface antigen , HIV1 HIV2 antibody Patients galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>